Results 131 to 140 of about 40,259 (213)

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials. [PDF]

Front Cardiovasc Med
Abunada A, Shah M, Kumar A, Lamiya Mir S, Kumar D, Ahmed S, Tanzeel M, Kumar V, Meghjiani A, Siddiqui MBA, Khatri G, Rai A, Deepak F, Kumar A.   +13 more
europepmc   +1 more source

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials. [PDF]

Open Heart
Aman A, Akram A, Akram B, Maham M, Bokhari MZ, Akram A, Akram S, Yaqub F.   +7 more
europepmc   +1 more source

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort. [PDF]

Rev Cardiovasc Med
Amr A, Kayvanpour E, Reich C, Koelemen J, Asokan S, Frey N, Meder B, Sedaghat-Hamedani F.   +7 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +1 more source

Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]

JACC Case Rep
Polizzi R, Canciello G, Ordine L, Lombardi R, Esposito G, Losi MA.   +5 more
europepmc   +1 more source

A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]

, 2017
et al,, Yee, Derek
core   +1 more source

Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy-a case of targeted therapy beyond left ventricular outflow tract obstruction. [PDF]

Front Med (Lausanne)
Yang L, Dai H, Rong Y.
europepmc   +1 more source

Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report. [PDF]

Case Rep Cardiol
Murthy N, Diep B, Evans J, Abramov D, Tran D.   +4 more
europepmc   +1 more source

Still at sea: a patient's ongoing journey with non-obstructive hypertrophic cardiomyopathy. [PDF]

Eur Heart J Case Rep
Goldie FC, Myles RC, Coats CJ.
europepmc   +1 more source